Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Small

Showing results (871-880 of 1,203) with videos related to

Pageof 121
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2006
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancerEric J Small, Paul F Schellhammer, Celestia S Higano, et al.
Journal of Consulting and Clinical Psychology|October 24, 2022
Change during cognitive and exposure phases of cognitive-behavioral therapy for autistic youth with anxiety disordersAndrew G Guzick, Sophie C Schneider, Philip C Kendall, et al.
Elife|November 16, 2022
The <i>CIC-ERF</i> co-deletion underlies fusion-independent activation of ETS family member, ETV1, to drive prostate cancer progressionNehal Gupta, Hanbing Song, Wei Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2006
Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162)Maha Hussain, Catherine M Tangen, Celestia Higano, et al.
Cancer Research|January 17, 2009
Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSFLawrence Fong, Serena S Kwek, Shaun O'Brien, et al.
Urology|August 16, 2005
Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 studyMary-Ellen Taplin, Daniel J George, Susan Halabi, et al.
Oncology Reports|October 6, 2011
A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancerTerence W Friedlander, Vivian K Weinberg, Yong Huang, et al.
Rejuvenation Research|October 19, 2013
Nutraceutical intervention improves older adults' cognitive functioningBrent J Small, Kerri S Rawson, Christina Martin, et al.
JAMA Psychiatry|July 2, 2016
Efficacy of Augmentation of Cognitive Behavior Therapy With Weight-Adjusted d-Cycloserine vs Placebo in Pediatric Obsessive-Compulsive Disorder: A Randomized Clinical TrialEric A Storch, Sabine Wilhelm, Susan Sprich, et al.
Cancer Research|November 21, 2024
Cancer-Related Cognitive Impairment and the Potential of Dietary Interventions for the Prevention and Mitigation of NeurodegenerationSylvia L Crowder, Lisa M Gudenkauf, Aasha I Hoogland, et al.
Pageof 121

Showing results (871-880 of 1,203) with videos related to

Sort By:
Pageof 121
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2006
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancerEric J Small, Paul F Schellhammer, Celestia S Higano, et al.
Journal of Consulting and Clinical Psychology|October 24, 2022
Change during cognitive and exposure phases of cognitive-behavioral therapy for autistic youth with anxiety disordersAndrew G Guzick, Sophie C Schneider, Philip C Kendall, et al.
Elife|November 16, 2022
The <i>CIC-ERF</i> co-deletion underlies fusion-independent activation of ETS family member, ETV1, to drive prostate cancer progressionNehal Gupta, Hanbing Song, Wei Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2006
Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162)Maha Hussain, Catherine M Tangen, Celestia Higano, et al.
Cancer Research|January 17, 2009
Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSFLawrence Fong, Serena S Kwek, Shaun O'Brien, et al.
Urology|August 16, 2005
Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 studyMary-Ellen Taplin, Daniel J George, Susan Halabi, et al.
Oncology Reports|October 6, 2011
A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancerTerence W Friedlander, Vivian K Weinberg, Yong Huang, et al.
Rejuvenation Research|October 19, 2013
Nutraceutical intervention improves older adults' cognitive functioningBrent J Small, Kerri S Rawson, Christina Martin, et al.
JAMA Psychiatry|July 2, 2016
Efficacy of Augmentation of Cognitive Behavior Therapy With Weight-Adjusted d-Cycloserine vs Placebo in Pediatric Obsessive-Compulsive Disorder: A Randomized Clinical TrialEric A Storch, Sabine Wilhelm, Susan Sprich, et al.
Cancer Research|November 21, 2024
Cancer-Related Cognitive Impairment and the Potential of Dietary Interventions for the Prevention and Mitigation of NeurodegenerationSylvia L Crowder, Lisa M Gudenkauf, Aasha I Hoogland, et al.
Pageof 121